Hims & Hers Health (NYSE:HIMS) Shares Gap Down After Analyst Downgrade

Hims & Hers Health, Inc. (NYSE:HIMS)’s share price gapped down prior to trading on Monday after Bank of America lowered their price target on the stock from $26.00 to $21.00. The stock had previously closed at $23.02, but opened at $17.83. Bank of America currently has an underperform rating on the stock. Hims & Hers Health shares last traded at $17.2790, with a volume of 40,482,980 shares changing hands.

A number of other research firms also recently weighed in on HIMS. KeyCorp initiated coverage on Hims & Hers Health in a research note on Tuesday, October 21st. They issued a “sector weight” rating for the company. Citigroup reissued a “sell” rating on shares of Hims & Hers Health in a report on Monday, January 5th. Evercore initiated coverage on shares of Hims & Hers Health in a research report on Monday, January 12th. They set an “in-line” rating and a $33.00 price target on the stock. BTIG Research cut their target price on Hims & Hers Health from $85.00 to $60.00 and set a “buy” rating for the company in a research report on Monday, February 2nd. Finally, UBS Group set a $32.00 price target on shares of Hims & Hers Health in a report on Tuesday, November 4th. One investment analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, nine have assigned a Hold rating and four have given a Sell rating to the stock. According to MarketBeat.com, Hims & Hers Health has an average rating of “Hold” and a consensus target price of $41.77.

Insider Activity

In other Hims & Hers Health news, CFO Oluyemi Okupe sold 23,187 shares of the company’s stock in a transaction dated Monday, November 17th. The shares were sold at an average price of $36.81, for a total transaction of $853,513.47. Following the transaction, the chief financial officer owned 70,232 shares in the company, valued at approximately $2,585,239.92. This represents a 24.82% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Deborah M. Autor sold 7,054 shares of the firm’s stock in a transaction that occurred on Wednesday, December 17th. The stock was sold at an average price of $36.71, for a total transaction of $258,952.34. Following the completion of the sale, the insider owned 6,175 shares in the company, valued at $226,684.25. This represents a 53.32% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 129,337 shares of company stock valued at $4,651,648. 13.71% of the stock is currently owned by insiders.

Hims & Hers Health News Summary

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: Hims voluntarily halted sales of its compounded semaglutide pill, which may limit immediate regulatory enforcement risk and legal exposure compared with continuing sales. Read More.
• Positive Sentiment: The quick pullback could preserve capital and reduce near-term operational disruption while management addresses compliance and legal issues. Read More.
• Neutral Sentiment: Analysts and commentators are questioning how much GLP‑1 related revenue Hims can reliably generate going forward; more skeptical research pieces suggest secular revenue uncertainty for the company’s obesity‑drug strategy. Read More.
• Negative Sentiment: Novo Nordisk filed a patent‑infringement lawsuit seeking to block Hims from selling compounded versions of its drugs and to recover damages — a direct legal threat that raises the risk of injunctive relief and large liabilities. Read More.
• Negative Sentiment: Market reaction: Hims shares moved sharply lower in premarket trading after the product pull and legal threats, reflecting investor concern about lost new‑product revenue and regulatory/legal risk. Read More.
• Negative Sentiment: Bank of America cut its price target to $21 and moved to an “underperform” rating, signaling analyst conviction that downside remains and adding selling pressure. Read More.

Institutional Investors Weigh In On Hims & Hers Health

Hedge funds and other institutional investors have recently modified their holdings of the stock. Quent Capital LLC purchased a new position in Hims & Hers Health during the third quarter valued at approximately $28,000. Binnacle Investments Inc bought a new stake in shares of Hims & Hers Health in the 3rd quarter worth about $28,000. Virtus Advisers LLC bought a new stake in Hims & Hers Health in the second quarter worth $26,000. Quaker Wealth Management LLC bought a new position in shares of Hims & Hers Health during the second quarter valued at approximately $29,000. Finally, Bessemer Group Inc. grew its holdings in shares of Hims & Hers Health by 105.8% in the second quarter. Bessemer Group Inc. now owns 607 shares of the company’s stock worth $30,000 after purchasing an additional 312 shares during the last quarter. 63.52% of the stock is currently owned by hedge funds and other institutional investors.

Hims & Hers Health Trading Down 25.9%

The company has a current ratio of 1.88, a quick ratio of 1.64 and a debt-to-equity ratio of 1.67. The firm has a market capitalization of $3.89 billion, a P/E ratio of 31.91, a price-to-earnings-growth ratio of 3.79 and a beta of 2.43. The stock has a 50-day simple moving average of $32.96 and a two-hundred day simple moving average of $43.32.

Hims & Hers Health announced that its board has authorized a share buyback program on Monday, November 17th that allows the company to repurchase $250.00 million in outstanding shares. This repurchase authorization allows the company to reacquire up to 3% of its stock through open market purchases. Stock repurchase programs are typically a sign that the company’s board of directors believes its shares are undervalued.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.